23:03 , Jun 29, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

New Therapeutic Targets and Biomarkers: June 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2017. Therapeutic targets are defined as any protein, gene or other...
16:32 , Jun 20, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection Mouse studies suggest promoting the expression of PYDC2 could help treat bacterial infections. In mouse models of Francisella novicida , F. tularensis and Streptococcus pneumoniae infection, transgenic overexpression of human PYDC2 in...
07:00 , May 22, 2014 |  BC Innovations  |  Cover Story

Ob(nox)ious fibrosis

Although Esbriet pirfenidone, the only marketed drug for idiopathic pulmonary fibrosis, has shown a mortality benefit, the effects are modest and there remains room for improvement. New preclinical findings suggest that inhibiting NADPH oxidase 4...
08:00 , Dec 24, 2012 |  BioCentury  |  Emerging Company Profile

Savant HWP: Antagonizing addiction

Savant HWP Inc. has developed selective antagonists of the nicotinic acetylcholine receptor alpha(3)beta(4) it believes could treat a wide variety of addiction disorders because the compounds hit a pathway that underlies most pleasure-seeking behaviors, including...
07:00 , Sep 20, 2012 |  BC Innovations  |  Targets & Mechanisms

Stabilizing RyR2

A group at Columbia University has found that preventing the leak of calcium ions from ryanodine receptors could help treat post-traumatic stress disorder, and a French team has found that the strategy could be effective...
07:00 , May 19, 2011 |  BC Innovations  |  Targets & Mechanisms

Thyroxine: MIFfed about sepsis

A U.S. research team has shown that d-thyroxine, an old hyperlipidemia drug from Abbott Laboratories , promotes survival in mouse models of sepsis by inhibiting the proinflammatory cytokine MIF . 1 The team is planning...
07:00 , May 16, 2011 |  BC Week In Review  |  Company News

Aegis Therapeutics, Albany Medical College deal

Aegis and the college partnered to create an oral formulation of the college's breast cancer candidate AFPep using Aegis' Intravail transmucosal intranasal drug delivery technology. Aegis, which said it is in discussions with oncology pharma...
08:00 , Feb 25, 2010 |  BC Innovations  |  Distillery Techniques

Technology: Computational models

Approach Summary Licensing status Publication and contact information Computational models Computational filters for removing poor drug development candidates from chemical libraries A computational system for removing poor drug development candidates from chemical libraries could help...
07:00 , Mar 26, 2009 |  BC Innovations  |  Tools & Techniques

Neural stem cells aplenty

Sloan-Kettering Institute researchers have developed a protocol for inducing neural cells that could alleviate some of the manufacturing and supply issues hindering the development of therapies, drug screening platforms and disease models that use human...
07:00 , May 15, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Pneumonia Interferon-g (IFN-g) A study in mice suggests that antagonizing pulmonary IFN-g produced during influenza infection could help prevent secondary...